Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

Immune cell populations of people with post-vaccination syndrome had lower levels of effector CD4 T cells and higher levels ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

New therapeutic 'cocktails' may provide long-lasting relief for treatment-resistant asthma and other immune system inflammatory diseases.

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

Current asthma treatments don't work in all patients, and they don't provide long-term relief from potentially deadly asthma ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

Researchers are tackling neutrophilic asthma, successfully developing one of the first mouse models of the condition.

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...